Table 3 Clinical trials of PDE inhibitors for cancer therapy (ClinicalTrials.gov)
From: cAMP-PKA/EPAC signaling and cancer: the interplay in tumor microenvironment
Trial ID | Regimen | Target | Cancer type | Phase | Outcome | References |
|---|---|---|---|---|---|---|
NCT01888952 | Roflumilast Prednisone | PDE4 | B-cell lymphoid malignancies | I | 66% patients had PR or SD | [402] |
NCT03458546 | Roflumilast R-CHOP | PDE4 | Diffuse large B-cell lymphoma | I | NA | |
NCT05796271 | Roflumilast R-CHOP | PDE4 | Diffuse large B-cell lymphoma | I | NA | |
NCT02544880 | Tadalafil Anti-MUC1 vaccine | PDE5 | Head and neck squamous cell carcinoma | I | The treatment combination is safe and well-tolerated | [405] |
NCT03238365 | Tadalafil Nivolumab | PDE5 | Head and neck squamous cell carcinoma | I | T lymphocyte and myeloid cell infiltration is enhanced | [406] |
NCT02466802 | Sildenafil Regorafenib | PDE5 | Solid tumors | I | Regorafenib can be safely combined with sildenafil | [407] |
NCT02279992 | Vardenafil Carboplatin | PDE5 | Gliomas and brain metastases | I | NA | |
NCT03993353 | Tadalafil Pembrolizumab | PDE5 | Head and neck cancer | II | NA | |
NCT01950923 | Sildenafil | PDE5 | Kidney cancer | I | NA | |
NCT05014776 | Tadalafil | PDE5 | Pancreatic cancer | II | NA | |
NCT03785210 | Tadalafil Nivolumab vancomycin | PDE5 | HCC and liver metastases from colorectal cancer or pancreatic ductal adenocarcinoma | II | OS: 9.4 m in HCC group; 3.4 m in liver metastases group | |
NCT04069936 | Tadalafil Nivolumab MILs™ | PDE5 | Non-small-cell lung cancer | II | NA | |
NCT01817751 | Tadalafil Sorafenib Valproic acid | PDE5 | Glioma | II | 6.4% of participants met 12-m PFS | |
NCT00843635 | Tadalafil | PDE5 | Cancer of the oral cavity or oropharynx | Not applicable | NA | |
NCT00752115 | Sildenafil Paclitaxel Carboplatin | PDE5 | Non-small-cell lung cancer | II/III | NA | |
NCT05709574 | Tadalafil Neoadjuvant FLOT | PDE5 | Gastric/gastroesophageal junction adenocarcinoma | II | NA | |
NCT01697800 | Tadalafil | PDE5 | Head and neck squamous cell carcinoma | II | NA |